Pramlintide
Also known as · Symlin · Amylin analogue
Overview
A stabilised analogue of amylin, the beta-cell hormone co-secreted with insulin. Used alongside mealtime insulin to blunt post-prandial glucose excursions and reduce food intake.
Research profile · for clinicians
Based on research: studied as a mealtime adjunct in both type 1 and type 2 diabetes. Literature focuses on post-prandial glucose smoothing, gastric emptying, and satiety-driven weight reduction.
Mechanism of action
Activates amylin receptors in the area postrema, slowing gastric emptying, suppressing post-prandial glucagon, and promoting central satiety independent of the GLP-1 pathway.
Research record
- [01]Reduced post-prandial glucose excursions and insulin requirements in type 1 diabetes trials.
- [02]Amylin-agonist combination work underpins the modern cagrilintide programmes.
Selected references
Pramlintide as an adjunct to insulin therapy
Diabetes Care, 2003
Research deep dive
Every cited study, explained
Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.